DAE HWA Pharmaceutical financial statements

대화제약KRX:067080 · KOSDAQ · Healthcare · sector #23
₩12,000-1.07%
2026-10-08 close

DAE HWA Pharmaceutical's published financial data is dated 2026-10-04. 2024 revenue was KRW 149.41B. 2024 operating profit was KRW 6.22B.

Reported results

Financial safety

Reference indicatorAs of 2024
Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -0.40
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
-0.40
Beneish M-Score
-2.78

No statistical flag

Sloan accrual
-2.72%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

9/9Strong

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score9/9

Profitability

  • Positive ROAPass
  • Positive OCFPass
  • Improving ΔROAPass
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtPass
  • Higher current ratioPass
  • No new sharesPass

Efficiency

  • Higher gross marginPass
  • Higher asset turnoverPass

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Margin trendWarning

영업외손익 급변 (영업이익 대비 46% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
4.2%
Interest coverage
1.1x
Return on equity (ROE)
0.7%

Operating margin −5pp

Operating loss
Interest coverageBase 1.1x adverse case -0.2x
Return on equity (ROE)Base 0.7% adverse case -9.3%

Revenue −15%

Interest coverage risk
Interest coverageBase 1.1x adverse case 1x
Return on equity (ROE)Base 0.7% adverse case -0.2%

Interest rate +2pp

Interest coverage risk
Interest coverageBase 1.1x adverse case 0.8x
Return on equity (ROE)Base 0.7% adverse case -2.7%

Interest coverage limit

Current margin 0.5pp

Interest coverage limit at an operating margin of 3.7%

Interest expense coverage threshold

DAE HWA Pharmaceutical notifications

Quantus Signal · live data · not investment advice · Privacy Policy